Venus Remedies Limited (BOM:526953)
India · Delayed Price · Currency is INR | Market Cap | 19.54B +229.8% |
| Revenue (ttm) | 8.37B +19.8% |
| Net Income | 1.22B +73.1% |
| EPS | 91.03 +72.9% |
| Shares Out | 13.37M |
| PE Ratio | 16.06 |
| Forward PE | n/a |
| Dividend | 10.00 (0.68%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 2,347 |
| Open | 1,525.00 |
| Previous Close | 1,454.15 |
| Day's Range | 1,420.05 - 1,525.90 |
| 52-Week Range | 439.10 - 2,043.15 |
| Beta | 0.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 26, 2026 |
About Venus Remedies
Venus Remedies Limited engages in the pharmaceutical business in India, Latin America, Europe, the Middle East, Africa, Asia, and internationally. The company is involved in the research and development of solutions focusing on antimicrobial resistance, oncology, skin and wound care, and pain management. It also provides analgesic, analgesic and antipyretic, antibiotic, antidiabetic anticoagulant, antiemetic, antiviral, cardiac, cardiovascular, CNS, disinfectant and antiseptic, gastro therapy, gastro therapy, hepatoprotective, hormones (steroid... [Read more]
Financial Performance
In fiscal year 2026, Venus Remedies's revenue was 7.70 billion, an increase of 17.88% compared to the previous year's 6.53 billion. Earnings were 1.03 billion, an increase of 126.83%.
Financial StatementsNews
Venus Remedies announces special window for re-lodgement of physical share transfers
Venus Remedies has announced the opening of a special window for the re-lodgement of transfer requests for physical shares. This initiative is in accordance with the Securities and Exchange Board…
Venus Remedies urges shareholders to update KYC details via social media
Venus Remedies has initiated a social media campaign to encourage its shareholders to update their KYC details. The company has utilised platforms such as Instagram, Facebook, LinkedIn, and X to…
Venus Remedies secures renewal of DSIR in-house R&D recognition
Venus Remedies Limited has successfully renewed its in-house Research & Development recognition from the Department of Scientific and Industrial Research (DSIR), Government of India. This renewal is f...
Venus Remedies hits 5% upper circuit at all-time high as FY26 profit more than doubles to ₹102.78 crore
Shares of Venus Remedies Limited hit a 5% upper circuit at ₹1,219.10 on May 27, touching a fresh all-time high, after the pharmaceutical company reported a sharp improvement in profitability…
Venus Remedies announces ₹10 per share final dividend with record date set for August 2026
Venus Remedies has announced a final dividend of ₹10 per equity share, equivalent to 100% of the face value, subject to shareholder approval at the forthcoming 37th Annual General Meeting…
Venus Remedies schedules AGM for August 2026 and announces dividend
Venus Remedies has announced the scheduling of its 37th Annual General Meeting (AGM) for 20th August 2026. The meeting will be conducted through video conferencing and other audio-visual means, adheri...
Venus Remedies shares rally 4% after Saudi Arabia approves oncology drug Plerixafor for global marketing authorization
Shares of Venus Remedies Limited witnessed a strong bullish wave in today’s trading session, surging over 4% to hit an intraday high of ₹1,077.80. The sudden price movement followed a…
Venus Remedies receives Saudi FDA approval for Plerixafor
Venus Remedies Limited has secured its first Marketing Authorization for Plerixafor from the Saudi Food and Drug Authority (SFDA), marking a significant milestone for the company. This approval repres...
Venus Remedies promotes KYC awareness through social media
Venus Remedies has launched a social media campaign to raise awareness among its shareholders about the importance of updating their KYC (Know Your Customer) details with the company. The initiative…
Venus Remedies renews GMP certification from Ukraine’s SMDC for Baddi facility
Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a pharmaceutical manufacturer headquartered in India, has renewed its Good Manufacturing Practices (GMP) certification from the State Service of Uk...
Venus Remedies shares jump 11% after US FDA grants QIDP status to novel antibiotic VRP-034
Shares of Venus Remedies surged over 11% in Wednesday’s trade, climbing to ₹347.65 on the NSE, after the company announced that its novel antibiotic formulation VRP-034 has received Qualified Infectio...
Venus Remedies gets US FDA grants QIDP status to novel polymyxin B formulation VRP-034
Venus Remedies Limited has received a significant regulatory boost with the United States Food and Drug Administration (US FDA) granting Qualified Infectious Disease Product (QIDP) designation to its ...
Venus Remedies secures exclusive rights for MET-X clinical development in India
Venus Remedies Ltd, a renowned Indian pharmaceutical company specializing in antimicrobial resistance (AMR), has entered into an exclusive licensing agreement with UK-based Infex Therapeutics. This co...
Venus Remedies shares surge 10% after EU GMP Certification renewal
Venus Remedies saw its shares jumped 10% after securing the renewal of its European Good Manufacturing Practices (EU GMP) certification from Infarmed, Portugal’s National Authority of Medicines and He...
Venus Remedies successfully renews EU GMP certification, reinforcing its European market presence
Venus Remedies Limited has announced the successful renewal of its European Good Manufacturing Practices (EU GMP) certification. Granted by Infarmed, the National Authority of Medicines and Health Pro...
Venus Remedies stock jumps 4% after receiving GMP certification for Antibiotic facility
Shares of Venus Remedies surged 4% after the company received a Good Manufacturing Practice (GMP) certification from the Ministry of Health of Moldova for its carbapenem antibiotic facility. This cert...
Venus Remedies shares surge 6% on Pemetrexed marketing authorization in Philippines
Venus Remedies’ stock jumped 6% following the announcement of marketing authorization for Pemetrexed 500mg, a chemotherapy agent used to treat lung cancer and mesothelioma, in the Philippines. This ap...